[go: up one dir, main page]

AU2002342672A1 - Method for screening for inhibitors of protein/protein interaction and corresponding ribozymes - Google Patents

Method for screening for inhibitors of protein/protein interaction and corresponding ribozymes

Info

Publication number
AU2002342672A1
AU2002342672A1 AU2002342672A AU2002342672A AU2002342672A1 AU 2002342672 A1 AU2002342672 A1 AU 2002342672A1 AU 2002342672 A AU2002342672 A AU 2002342672A AU 2002342672 A AU2002342672 A AU 2002342672A AU 2002342672 A1 AU2002342672 A1 AU 2002342672A1
Authority
AU
Australia
Prior art keywords
protein
inhibitors
screening
corresponding ribozymes
interaction
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002342672A
Inventor
Michael Famulok
Jorg Hartig
Seyed Hani Najafi-Shoushtari
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
NascaCell GmbH
Original Assignee
NascaCell GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE10144647A external-priority patent/DE10144647A1/en
Application filed by NascaCell GmbH filed Critical NascaCell GmbH
Publication of AU2002342672A1 publication Critical patent/AU2002342672A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/12Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
    • C12N2310/122Hairpin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AU2002342672A 2001-09-11 2002-09-10 Method for screening for inhibitors of protein/protein interaction and corresponding ribozymes Abandoned AU2002342672A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DE10144647.0 2001-09-11
DE10144647A DE10144647A1 (en) 2001-09-11 2001-09-11 New allosterically regulatable hairpin ribozyme, useful for identifying compounds that bind specific targets, has extra sequence between substrate binding and catalytic domains
DE10229393.7 2002-06-29
DE10229393 2002-06-29
PCT/EP2002/010140 WO2003022858A2 (en) 2001-09-11 2002-09-10 Method for screening for inhibitors of protein/protein interaction and corresponding ribozymes

Publications (1)

Publication Number Publication Date
AU2002342672A1 true AU2002342672A1 (en) 2003-03-24

Family

ID=26010109

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002342672A Abandoned AU2002342672A1 (en) 2001-09-11 2002-09-10 Method for screening for inhibitors of protein/protein interaction and corresponding ribozymes

Country Status (2)

Country Link
AU (1) AU2002342672A1 (en)
WO (1) WO2003022858A2 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7115396B2 (en) 1998-12-10 2006-10-03 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
EP1539941A4 (en) * 2002-08-27 2006-11-29 Adzymes and uses thereof
JP5006651B2 (en) 2003-12-05 2012-08-22 ブリストル−マイヤーズ スクウィブ カンパニー Inhibitor of type 2 vascular endothelial growth factor receptor
AU2007325838B2 (en) 2006-11-22 2013-09-19 Bristol-Myers Squibb Company Targeted therapeutics based on engineered proteins for tyrosine kinases receptors, including IGF-IR
CN102007145A (en) 2008-02-14 2011-04-06 百时美施贵宝公司 Targeted therapeutics based on engineered proteins that bind egfr
AR071874A1 (en) 2008-05-22 2010-07-21 Bristol Myers Squibb Co ARMAZON DOMAIN PROTEINS BASED ON MULTIVALENT FIBRONECTINE
TWI496582B (en) 2008-11-24 2015-08-21 必治妥美雅史谷比公司 Bispecific egfr/igfir binding molecules
TW201138808A (en) 2010-05-03 2011-11-16 Bristol Myers Squibb Co Serum albumin binding molecules
EP3091028A1 (en) 2010-05-26 2016-11-09 Bristol-Myers Squibb Company Fibronectin based scaffold proteins having improved stability
ES2736127T3 (en) 2014-03-20 2019-12-26 Bristol Myers Squibb Co Type III domains of seroalbumin binding fibronectin
CN108290941A (en) 2015-09-23 2018-07-17 百时美施贵宝公司 The seralbumin associativity fibronectin type III domain of fast dissociation rate

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA88227B (en) * 1987-01-28 1988-06-30 Warner-Lambert Company Thrombin preparations
US4959212A (en) * 1988-06-22 1990-09-25 Alexandra Stancesco Oxidizing-energizing composition and method for the treatment of diabetes
IT1243358B (en) * 1990-07-23 1994-06-10 Iketon Farmaceutici Srl PHARMACEUTICAL COMPOSITIONS FOR THE ORAL ADMINISTRATION OF IRUDINA
US5900407A (en) * 1997-02-06 1999-05-04 Inspire Pharmaceuticals, Inc. Method of treating dry eye disease with uridine triphosphates and related compounds
EP1356105A2 (en) * 2000-11-22 2003-10-29 NascaCell GmbH Method for identifying compounds or lead structures against rna target motifs and rna/protein interactions

Also Published As

Publication number Publication date
WO2003022858A2 (en) 2003-03-20
WO2003022858A3 (en) 2003-08-28

Similar Documents

Publication Publication Date Title
AU2002316137A1 (en) Method of determining protein interaction inhibitors
AU2002238005A1 (en) Method and apparatus for securing portions of memory
AU2002366096A1 (en) Apparatus and method for eliminating dislodged thrombus
AU2002362197A1 (en) Method of stabilizing protein
AU2002303488A1 (en) Method and apparatus for determining spatial relation of multiple implantable electrodes
AU2002353612A1 (en) System and method of international patent application
AU4256901A (en) Method of screening for inhibitors of osteopontin
AU2002319790A1 (en) Particulate addition method and apparatus
AU2002305927A1 (en) Apparatus and method for designing proteins and protein libraries
AU2002249984A1 (en) Peptide or protein microassay method and apparatus
AU2002342672A1 (en) Method for screening for inhibitors of protein/protein interaction and corresponding ribozymes
AU2002354462A1 (en) Apparatus for predicting stereostructure of protein and prediction method
AU2003225084A1 (en) Method and apparatus for redirection of operations between interfaces
AU2002367604A1 (en) Apparatus and method for designing proteins and protein libraries
AU2002305092A1 (en) Method and system for high-throughput screening
EP1308542A3 (en) Method and apparatus for crystallization of proteins and the like
AU2003247442A1 (en) Apparatus and method for relative or quantitative comparison of multiple samples
AU2002255881A1 (en) Method of screening for agents that regulate the shedding of membrane bound proteins and methods of use
AU2002341828A1 (en) Enhanced proteins and methods for their use
AU2002354363A1 (en) Method of activating protein
AU2001249434A1 (en) Method and apparatus for predicting structure of transmembrane proteins
AU2002213954A1 (en) Method for the selective modification of peptides and proteins
AU2001278688A1 (en) P53-dependent novel apoptosis-associated protein and method of screening apoptosis controlling agent
AU2001267834A1 (en) Method of evaluating useful cattle
AU2003304539A1 (en) Protein library and screening method using the same

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase